Loading
Infant leukaemia is driven almost entirely by KMT2A fusions, which menin inhibitors were built to attack. Add them to the new blinatumomab-containing backbone.
Infant ALL EFS plateaued below 50% for two decades; blinatumomab (Interfant-21) is the first step forward. Revumenib is approved for KMT2Ar acute leukaemia including children ≥1 year and has paediatric formulation data; combining with chemotherapy and blinatumomab in the first year of life is the obvious next trial.
One of the most cited trial reports Europe PMC returns for Blinatumomab in Acute lymphoblastic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Blinatumomab in Acute lymphoblastic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for Blinatumomab in Acute lymphoblastic leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares KMT2A (MLL) rearrangement, Ziftomenib, Revumenib, Menin.
Shares Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study, Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, Blinatumomab, Acute lymphoblastic leukaemia.
Shares AUGMENT-101, KMT2A (MLL) rearrangement, Ziftomenib, Revumenib.
Shares KMT2A (MLL) rearrangement, Ziftomenib, Revumenib, Menin.
Shares Ziftomenib, Revumenib, Menin, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year).
Shares AUGMENT-101, Revumenib, Menin, Acute lymphoblastic leukaemia.
Shares KMT2A (MLL) rearrangement, Ziftomenib, Revumenib, Menin.
Shares AUGMENT-101, Revumenib, Menin, Acute lymphoblastic leukaemia.